Description
📦 Shipping:
USA:
⏱ Estimated Delivery: 1-2 weeks
International:
⏱ Estimated Delivery: 1-2 weeks
Products are shipping without brand labels for security reasons.
Cagrilintide is a next-generation investigational peptide designed for appetite regulation and weight management. It is a long-acting amylin analogue (often described as an amylin receptor agonist) developed to help people feel full sooner, stay satisfied for longer, and reduce overall calorie intake through improved satiety signalling.
Unlike stimulant-style “fat burners,” cagrilintide targets the body’s natural fullness pathways. In clinical studies in adults with overweight/obesity, once-weekly cagrilintide produced meaningful reductions in body weight and was generally well tolerated, supporting its development as a novel mechanism for weight management.
This 5mg vial contains pharmaceutical-grade Cagrilintide, securely shipped worldwide from AlphaMuscle.is.
Key Benefits
-
Potential benefits (based on clinical research and mechanism):
-
Reduced appetite and cravings through stronger satiety signalling
-
Earlier fullness and improved portion control
-
Support for sustained calorie deficit by helping reduce hunger “noise”
-
Once-weekly dosing in trials, improving adherence versus daily protocols
Important: individual results vary, and side effects can occur. Cagrilintide is an investigational medicine (not a routine OTC supplement).
-
How It Works
Amylin is a hormone co-secreted with insulin that contributes to satiety (the feeling of being satisfied after eating). Cagrilintide is engineered to mimic and extend this effect, acting on central appetite pathways that influence food intake and body weight regulation.
In simple terms, it aims to:
-
Increase fullness signals after meals
-
Reduce the drive to keep eating past satisfaction
-
Potentially slow gastric emptying in a way that supports satiety (a feature commonly associated with amylin biology)
Dosage & Cycle Plan (Informational Purposes)
This section is for education, based on published trial designs — not a recommendation for self-use. Always follow a qualified clinician’s advice.
In a phase 2 dose-finding programme, cagrilintide was studied at 0.3, 0.6, 1.2, 2.4 and 4.5 mg once weekly.
A commonly reported dose-escalation schedule in trial documentation started at 0.6 mg, then increased every 2 weeks to 1.2 mg, then 2.4 mg, then 4.5 mg for the remainder of the study period.
Cagrilintide vs Semaglutide
Semaglutide (a GLP-1 receptor agonist) primarily reduces appetite and improves glucose regulation via GLP-1 pathways. Cagrilintide targets amylin satiety pathways, which may feel different subjectively (often described as “fullness” and “reduced interest in food”).
Because these pathways are complementary, Novo Nordisk has studied co-administration of cagrilintide + semaglutideand developed a fixed-dose combination concept (often referred to as CagriSema). Published and registry materials describe this as combining GLP-1 and amylin analogue activity, with trials showing greater weight loss than semaglutide alone in certain study settings.
Advantages:
-
Stronger satiety / fullness: tends to make you feel “done” sooner when eating.
-
Reduced appetite “food noise”: less constant thinking about food for some users.
-
Craving control: may reduce snacking and impulsive eating by increasing satisfaction after meals.
-
Portion control support: easier to stick to smaller portions without feeling as deprived.
-
Non-stimulant approach: not a jittery “fat burner” style product; works via appetite signalling rather than stimulation.
-
Once-weekly dosing in studies: long-acting design can be more convenient than daily protocols (depending on the specific regimen).
-
Complementary to GLP-1s: targets a different pathway than semaglutide (amylin vs GLP-1), which is why the combo approach (often referred to as “CagriSema”) has been explored.
-
May help adherence to a calorie deficit: because hunger is often the biggest reason people break a cut.
Frequently Asked Questions
Is cagrilintide approved for weight loss?
Cagrilintide has been studied in clinical trials, and combination programmes have been progressing through regulatory pathways.
How quickly do people notice appetite changes?
In research settings, appetite effects can appear during early dose escalation, but timing varies widely. Side effects and adherence also influence outcomes.
What are the most common side effects?
As with other satiety-signalling injectables, gastrointestinal effects (e.g., nausea) are commonly discussed in trial contexts. If severe symptoms occur, medical advice is essential.
Do I still need diet and exercise?
Yes. These medicines are typically studied alongside lifestyle measures (nutrition, activity, behaviour change). They’re best viewed as support tools, not replacements.
Can it be used with semaglutide?
Combination use has been studied in clinical research; however, combining prescription injectables should only be done under clinician supervision due to side-effect risk and monitoring requirements.
Why Buy from AlphaMuscle
-
Pharmaceutical-grade purity
-
Lab-tested identity & potency
-
Worldwide discreet shipping
-
Trusted source for GLP-1, GIP, and fat loss peptides
